[Pyelectasy].

B Langer

Home/Archive/PubMed

PubMed · 12843877

[Pyelectasy].

B Langer

View original source ↗Export metadata ↓

Abstract

Ultrasonography is undoubtedly an effective tool for identifying fetal urinary tract anomalies. Fetal pyelic dilatations are common and of controversial pathological significance. A 5 mm threshold for a pelvic anteroposterior diameter can be used to detect dilatation during the second trimester of pregnancy, if, and only if, all suspected dilatations are verified during the third trimester. Only the dilatations larger than 10 mm after 28 weeks merit further postnatal exploration. Urological postnatal exploration should be done if the abnormalities persist at the postnatal sonographic control. This control, if normal, should be repeated at least once at the age of one month. Further investigations are necessary to evaluate the incidence and significance of VUR, since it has been reported associated in certain cases with isolated pyelic dilatation. However, there are no grounds at present for justifying routine retrograde cystography in case of an isolated fetal pyelic dilatation. A karyotype study is not indicated in the presence of an isolated pyelic dilatation.

Explore related subjects

Age Factors Chromosome Aberrations Dilatation, Pathologic Female Gestational Age Humans Incidence Karyotyping Kidney Pelvis Perinatal Care Predictive Value of Tests Pregnancy Pregnancy Trimester, Second Ultrasonography, Prenatal Urodynamics Vesico-Ureteral Reflux Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

B Langer. 2003. [Pyelectasy].. https://pubmed.ncbi.nlm.nih.gov/12843877/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.

Screening for prostate cancer using prostate-specific antigen (PSA) tests has led to a stage and grade shift as compared to the pre-PSA era. Effectiveness of screening for prostate cancer should be manifested by a reduction in detection rate of aggressive cancers during subsequent screening. In 6 centers of the European Randomized Screening study for Prostate Cancer, a total of 58,710 men were tested for prostate cancer. Screening centers differed with regard to age-range, screening interval and biopsy indications. During the 2nd visit, the proportion of Gleason score 6 cancers increased from 62.5 to 75%, mainly at the expense of Gleason score 7 cancers. High-grade (Gleason score 8-10) cancer detection rates varied per screening center during the 1st visit from 5.1 to 41.1, and during the 2nd visit from 6.4 to 29.3/10,000 men. The overall detection rate of high-grade cancers showed a reduction during the 2nd visit from 26 to 12/10,000 men, an effect mainly attributable to the screening center with the highest cancer detection rate (i.e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range.

Age Factors↗

PubMed2006

Development in incidence of breast cancer in non-screened Danish women, 1973-2002--a population-based study.

The authors report on the incidence rates of breast cancer overall and by histology in a population of unscreened women constituting approximately 80% of the total population of women in Denmark from 1973-2002, utilizing the files of the nationwide Danish Cancer Registry. The age-specific incidence rates of breast cancer increased throughout the period, and further, marked changes in the age-specific incidence pattern were observed, where the plateau and change of slope around the age of 46-48 in 1973-1981 shifted to around age 64-66 years in 1994-2002. Age-period-cohort modeling indicated that these changes were not attributable to a birth cohort effect. Although lobular breast cancer incidence increased more than ductal breast cancer incidence, this was only observed in the first decade after the introduction of the ICD-O system in Denmark and probably is attributable to this, whereas we observed no disproportionate changes by histology in any age group from 1988-2002. Thus, previous reports of a disproportionate increase in lobular breast cancer could not be confirmed in a non-screened population, whereas important changes over the past decade in the age-specific incidence pattern of breast cancer particular around the time of menopause were indicated.

Age Factors↗

PubMed2006

Risk of stroke and hormone replacement therapy. A prospective cohort study.

OBJECTIVE: The purpose of this study was to examine the risk of first-ever stroke in relation to use of hormone replacement therapy (HRT) among middle-aged and older Swedish women. MATERIALS: A total of 16,906 women, 45-73 years old, from the 'Diet and Cancer' study in Malmö, Sweden were examined. Women were considered as HRT users if they took systemic hormone therapy regularly. Incidence of stroke was followed for a mean period of 10.5 years. RESULTS: In all, 2148 (12.7%) women used HRT. A total of 461 stroke cases occurred during follow-up, 48 of them in HRT users. Incidence of total stroke and ischemic subtype had no significant relation to HRT use. However, an increased risk of hemorrhagic stroke was found in women taking unopposed estrogen (RR=2.55, 95%CI: 1.03-6.35) or un-native estrogen regimens (RR=4.27, 95%CI: 1.71-10.66). Although not significantly, the risk of stroke was 33% lower in women who started their treatment before menopause. Among HRT users, the risk of stroke was associated with advancing age, smoking, excess body weight and hypertension. CONCLUSIONS: There is no significant association between hormone therapy and risk of total stroke in women during 10.5 years follow-up. Preparations of estrogen and time for initiation of treatment may affect the risk of stroke.

Age Factors↗